Free Trial
OTCMKTS:BIOQ

Bioqual Q4 2025 Earnings Results & Report

Bioqual logo
$31.00 0.00 (0.00%)
As of 11/12/2026

Bioqual reported Q4 2025 earnings on September 19, 2025. The company reported EPS of -$0.11, while revenue was $11.67 million.

Earnings Announcement Details

Quarter
Q4 2025
Time
After Market Closes

Bioqual EPS Results

Actual EPS
-$0.11
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioqual Revenue Results

Actual Revenue
$11.67 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Bioqual Q4 2025 Earnings FAQ

Bioqual (OTCMKTS:BIOQ) reported earnings of -$0.11 per share for Q4 2025. The report was announced on Friday, September 19, 2025.

Bioqual reported revenue of $11.67 million for Q4 2025.

Bioqual Earnings Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
BIOQUAL Presents Financial Results for Fiscal Year 2026
See More Bioqual Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioqual? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioqual and other key companies, straight to your email.

About Bioqual

Bioqual (OTCMKTS:BIOQ), Inc. is a biomedical research and contract research organization based in the United States. The company provides preclinical research services to pharmaceutical and biotechnology companies, government agencies, and other organizations developing medical treatments, vaccines, and diagnostics.

Its activities include animal-model research, pharmacology, toxicology, infectious-disease studies, and vaccine and therapeutic efficacy testing. Bioqual has experience conducting research involving nonhuman primates and other laboratory animals, supporting the evaluation of potential products before they advance to human clinical trials.

The company’s services are designed to help clients assess safety, effectiveness, and biological responses across a range of medical and public-health applications. Publicly available information about Bioqual’s current leadership, geographic reach, and additional operating details is limited.

View Bioqual Profile